Microcarriers Market Analysis

Microcarriers Market Analysis

To get key market trends

  Download Free Sample

Based on product, the market is bifurcated into consumables and equipment. The consumables segment held the largest business share of 67.5% in 2023.
 

• Consumables align with the ongoing single-use trend, as they are designed for one-time use, thereby eliminating the need for complex cleaning and sterilization processes associated with reusable equipment. This trend has driven the adoption of consumables in the market.
   
• Additionally, consumables provide flexibility in scale-up scenarios. For instance, Sartorius AG offers microcarrier beads that are animal component free as well as animal protein coated for adherent cell culture. These microcarrier beads can be extensively used during various procedures and thus increases the utilization of consumables. Therefore, bioprocess engineers can easily scale cell culture operations by adding more units of pre-sterilized microcarriers as needed.
   

Based on application, the microcarrier market is classified into biopharmaceutical production, regenerative medicine, and other applications. The biopharmaceutical production is expected to exhibit 9.6% CAGR between 2024 and 2032.
 

• Biopharmaceuticals, including vaccine and therapeutic production, often require the large-scale cultivation of cells. As, microcarriers provide a platform for efficient and scalable cell culture, supporting the growth of cells needed to produce biopharmaceuticals.
   
• Also, various approval of biosimilars has led to the surge in the biopharmaceutical production processes and research pertaining to innovation. The microcarriers are scalable, and their use facilitates the upscaling of bioprocesses. Consequently, biopharmaceutical production often requires the transition from laboratory-scale experiments to larger production scales, and microcarriers support this scalability, thus escalating the segment expansion.
   

Based on end-user, the microcarrier market is divided into pharmaceutical & biotechnology companies, CROs & CMOs, academic & research institutes, and cell banks. The pharmaceutical & biotechnology companies’ segment is expected to reach the largest market revenue of USD 1.6 billion by 2032.
 

• The substantial demand for bioprocessing technologies, driven by the need for large quantities of biopharmaceuticals, has led pharmaceutical and biotechnology companies to be major consumers of microcarriers.
   
• Also, the development of cell-based therapies, including CAR-T cell therapies and other advanced cell therapies, is a growing area in biotechnology. Hence, usage of microcarriers may support the expansion and production of therapeutic cells needed for these innovative treatments.
   
• Additionally, the ongoing need for vaccines, including those for emerging infectious diseases, further propels the demand for microcarriers, with pharmaceutical companies driving advancements in vaccine manufacturing, thereby boosting the segment landscape.
   

In 2023, North America held a significant share of 40.7% in the microcarriers market.
 

• The region is home to a significant number of leading biopharmaceutical and biotechnology companies involved in research, development, and production of innovative therapeutics. These companies extensively use microcarriers in their bioprocessing and cell culture applications. Also, increasing adoption of biologics and biosimilars contribute to the demand for microcarriers.